Humana Stock Gets Increased EPS Forecast from Zacks Research

Humana logo with Healthcare background
Image from MarketBeat Media, LLC.

Humana Inc. (NYSE:HUM - Free Report) - Stock analysts at Zacks Research increased their FY2026 earnings per share estimates for shares of Humana in a research report issued to clients and investors on Thursday, November 19th. Zacks Research analyst Team now forecasts that the insurance provider will post earnings of $9.50 per share for the year, up from their prior estimate of $9.05. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Humana's current full-year earnings is $9.66 per share. Zacks Research also issued estimates for Humana's Q1 2028 earnings at $11.72 EPS and Q3 2028 earnings at $6.38 EPS.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.30. The business had revenue of $41.16 billion for the quarter, compared to analysts' expectations of $40.87 billion. Humana had a net margin of 0.81% and a return on equity of 8.50%. The company's revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the business earned $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS.

A number of other brokerages also recently weighed in on HUM. Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a report on Monday, November 9th. Raymond James Financial reiterated an "outperform" rating on shares of Humana in a research report on Friday, November 6th. Cantor Fitzgerald began coverage on Humana in a research note on Monday. They issued an "overweight" rating for the company. Bank of America raised shares of Humana from a "neutral" rating to a "buy" rating and set a $500.00 price target for the company in a research report on Wednesday, July 29th. Finally, Sanford C. Bernstein reiterated an "outperform" rating and issued a $515.00 price objective on shares of Humana in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $491.74.

Check Out Our Latest Stock Report on HUM

Humana Stock Performance

Shares of NYSE HUM opened at $380.60 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. The firm has a market cap of $45.71 billion, a P/E ratio of 37.02, a PEG ratio of 1.84 and a beta of 0.65. The stock has a fifty day moving average price of $409.87 and a two-hundred day moving average price of $321.41. Humana has a 1 year low of $163.11 and a 1 year high of $462.87.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, December 24th. Humana's dividend payout ratio (DPR) is currently 34.44%.

Insider Activity

In related news, insider Joseph Ventura sold 5,495 shares of the stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the sale, the insider owned 21,910 shares in the company, valued at approximately $9,505,653.50. This trade represents a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.20% of the company's stock.

Institutional Trading of Humana

Institutional investors have recently modified their holdings of the company. Vista Investment Partners LLC bought a new stake in shares of Humana in the 3rd quarter valued at $3,254,000. Manning & Napier Advisors LLC acquired a new stake in Humana in the second quarter worth $1,412,000. The Manufacturers Life Insurance Company grew its stake in shares of Humana by 10.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider's stock valued at $27,879,000 after buying an additional 6,690 shares during the period. Pzena Investment Management LLC bought a new stake in shares of Humana during the second quarter valued at approximately $1,749,014,000. Finally, Ameritas Advisory Services LLC acquired a new position in Humana during the second quarter worth $1,709,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Top Humana Stories

Here are a few of the latest stories about HUM:

  • Positive Sentiment: Morgan Stanley raised its price target to $475 from $370, implying upside from the level cited in the report, while keeping an “Equal Weight” rating. Morgan Stanley rating report
  • Neutral Sentiment: Humana launched a National Gold Card program intended to reduce prior-authorization requirements for some providers. It may ease administrative burdens, but the report offers no indication of a near-term financial impact. Humana launches National Gold Card Program
  • Negative Sentiment: The proposed CMS CRUSH rule would strengthen Medicare Advantage audits and recovery of unsupported risk-adjustment payments, including broader use of extrapolated recoveries. Because Medicare Advantage is central to Humana’s business, investors fear higher repayment exposure and future costs; the proposal has also pressured other health insurers. Humana shares slip after CMS fraud rule

About Humana

(Get Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Read More

Earnings History and Estimates for Humana (NYSE:HUM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Humana Right Now?

Before you consider Humana, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.

While Humana currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines